Study #2024-0197
NCI: Refining Tamoxifen dose for premenopausal breast cancer risk reduction (RENAISSANCE): A phase II single arm trial.
MD Anderson Study Status
Enrolling
Treatment Agent
Tamoxifen
Description
This phase II trial evaluates response-guided low-dose tamoxifen for reducing breast density in women who are at higher than average risk for breast cancer. Increasing breast density is a well established risk factor for breast cancer. Tamoxifen is a selective estrogen receptor modulator. It works by blocking the effects of the hormone estrogen in the breast. Tamoxifen has been shown to reduce breast density, even at reduced dosages, and is approved for the prevention of breast cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Study phase:
Phase II
Physician name:
Parijatham Thomas
Department:
Clinical Cancer Prevention
For general questions about clinical trials:
1-855-404-4637
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.